In Project 6 (formerly Project 2), we have been investigating gene-gene interactions in a large, extended (n=800) French Canadian, protein C deficient, thrombophilic family in which we have identified three genomic regions with significant linkage to thrombosis. This kindred has been demonstrated to have a small number of genes (one to three) interacting with protein C to cause thrombosis, thus characterizing thrombophilia in this family as an oligogenic disease. Oligogenic diseases offer attractive models for investigating multigenic diseases, in contrast to polygenic diseases like atherosclerosis which have numerous susceptibility genes, each of small effect. In this family the remaining heritability for thrombosis of 0.40, after correcting for the heritability of the protein C mutation, suggests that the unknown susceptibility gene(s) have an effect of about the same magnitude as protein C. Thus, the effect of the unknown gene(s) should be detectable by modern genomic strategies. In pursuing this strategy we have resequenced 109 candidate genes within the three genomic regions linked with thrombosis (about 50% of the genes in these regions) using a case control design. In our preliminary analysis of this rich database, using SNP genotyping on additional family members based on SNPs identified by resequencing, we have identified an attractive candidate gene by genetic epidemiological analysis with preliminary phenotypic corroboration from microarray experiments which compared endothelial cells cultured from affected family members with normal controls. The goals of this project are to: 1) thoroughly analyze the database of resequenced genes in the Vermont family with respect to an increasingly complex hierarchy of interacting susceptibility genes, 2) validate these findings in independent populations, 3) extend our investigation to the biological pathways implicated by the individual candidate genes identified in the Vermont kindred in cases where individual SNPs identified in the analysis of the family dataset are not reproduced in independent populations using a similar SNP genotyping and resequencing approach and 4) improve risk profiling so that individuals at increased risk for thrombosis due to identified genetic risk factors can receive appropriate intensity and duration of treatment for prophylaxis and for acute events. As candidate genes and the biological pathways they implicate are identified they will be explored in collaboration with the other investigators in the program project group. Relevance: This study will improve individual physician's ability to predict the risk for an individual patient to develop life threatening clots in their veins and therefore allow for more effective treatment of this life threatening disease. It will also decrease the number of serious chronic side effects that result from damage to the blood vessels which contain the clots.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL046703-18
Application #
7903922
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
18
Fiscal Year
2009
Total Cost
$210,893
Indirect Cost
Name
University of Vermont & St Agric College
Department
Type
DUNS #
066811191
City
Burlington
State
VT
Country
United States
Zip Code
05405
Kusak, Piotr; Czarnecka, Danuta; Gissel, Matthew et al. (2016) Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke. Arch Med Sci 12:1000-1007
Bouchard, Beth A; Chapin, John; Brummel-Ziedins, Kathleen E et al. (2015) Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency. Blood 125:3647-50
Brummel-Ziedins, Kathleen E; Everse, Stephen J; Mann, Kenneth G et al. (2014) Modeling thrombin generation: plasma composition based approach. J Thromb Thrombolysis 37:32-44
Bouchard, Beth A; Gissel, Matthew T; Whelihan, Matthew F et al. (2014) Platelets do not express the oxidized or reduced forms of tissue factor. Biochim Biophys Acta 1840:1188-93
de Haan, Hugoline G; Bezemer, Irene D; Vossen, Carla Y et al. (2014) Genetic variants in Cell Adhesion Molecule 1 (CADM1): a validation study of a novel endothelial cell venous thrombosis risk factor. Thromb Res 134:1186-92
Undas, A; Brummel-Ziedins, K E; Mann, K G (2014) Anticoagulant effects of statins and their clinical implications. Thromb Haemost 111:392-400
Whelihan, Matthew F; Kiankhooy, Armin; Brummel-Ziedins, Kathleen E (2014) Thrombin generation and fibrin clot formation under hypothermic conditions: an in vitro evaluation of tissue factor initiated whole blood coagulation. J Crit Care 29:24-30
Bouchard, B A; Abdalla, S; Tracy, P B (2013) The factor V light chain mediates the binding and endocytosis of plasma-derived factor V by megakaryocytes. J Thromb Haemost 11:2181-3
Brummel-Ziedins, K (2013) Models for thrombin generation and risk of disease. J Thromb Haemost 11 Suppl 1:212-23
Butenas, S; Krudysz-Amblo, J; Rivard, G E et al. (2013) Product-dependent anti-factor VIII antibodies. Haemophilia 19:619-25

Showing the most recent 10 out of 247 publications